Skip to main content
BOTANIX PHARMACEUTICALS LTD logo

BOTANIX PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · BOT ISIN · AU000000BOT2 ASX Manufacturing
Open in API
Filings indexed 1,208 across all filing types
Latest filing 2023-10-05 Regulatory Filings
Country AU Australia
Listing ASX BOT

About BOTANIX PHARMACEUTICALS LTD

https://botanixpharma.com/

Botanix Pharmaceuticals Ltd is a clinical-stage pharmaceutical company focused on the development and commercialization of novel topical treatments for serious skin conditions. The company utilizes its proprietary Permetrex™ skin delivery technology, which is designed to improve the delivery of active ingredients through the skin. Its primary product, Sofdra™ (sofpironium bromide), is an FDA-approved prescription topical gel for the treatment of primary axillary hyperhidrosis. The company's research and development pipeline also includes clinical-stage candidates for the treatment of acne, rosacea, and atopic dermatitis. Botanix aims to address significant unmet medical needs in dermatology by providing innovative therapeutic solutions with enhanced safety and efficacy profiles.

Recent filings

Filing Released Lang Actions
Section 708A(5)(e) Notice 2 pages 146.9KB
Regulatory Filings Classification · 95% confidence The document is a notice under section 708A(5)(e) of the Corporations Act 2001 (Cth) regarding the issuance of new shares following the exercise of options. It provides legal and regulatory compliance information about the share issue and the exemption from disclosure requirements. The document is short (2415 characters) and serves as a formal notification to the market rather than a detailed financial report or announcement of financial results. It does not contain financial statements, management discussion, or detailed capital structure updates beyond the share issuance notice. This fits the category of a Regulatory Filing (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2023-10-05 English
Appendix 4G and Corporate Governance Statement 22 pages 475.6KB
Regulatory Filings Classification · 95% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3. It is a form used by ASX-listed entities to confirm compliance with corporate governance disclosure requirements. The document includes a key to where governance disclosures can be found, and it explicitly states it is not a substitute for the corporate governance statement itself. The document is a regulatory filing related to governance disclosures but does not contain the full corporate governance statement or annual report. It is a compliance and verification tool submitted alongside the annual report. Given these characteristics, the document fits best under Regulatory Filings (RNS) as it is a regulatory compliance document and not the full governance report or annual report itself.
2023-09-28 English
Annual Report 76 pages 2.0MB
Annual Report Classification · 100% confidence The document is titled 'ANNUAL REPORT for the year ended 30 June 2023' and contains detailed sections typical of an annual report, including Directors' Report, Auditors Independence Declaration, Consolidated Financial Statements, Notes to the Financial Statements, Directors' Declaration, and Independent Audit Report. The content includes comprehensive financial data, management discussion, and corporate information for the full fiscal year ending June 30, 2023. The length of the document (15,000 characters) and the detailed financial and operational information confirm it is the full annual report rather than an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K).
2023-09-28 English
FDA Letter Requires Patient Instruction Update 4 pages 392.8KB
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Botanix Pharmaceuticals regarding the receipt of a Complete Response Letter (CRL) from the FDA related to its New Drug Application (NDA) for Sofpironium Bromide gel. It discusses the FDA's feedback, the nature of the issues (limited to patient instructions), the plan for resubmission, and the expected timeline for approval and commercial launch. The document includes detailed information about the regulatory process, clinical study results, and company plans, but it is not a full financial report or earnings release. It is also not a simple announcement of a report publication or a certification. The document is a regulatory update on a significant FDA communication affecting the company's product approval timeline. This type of document fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories. The document is over 10,000 characters, so it is not a brief announcement but a substantive regulatory update. Therefore, the appropriate classification is Regulatory Filings (RNS) with high confidence.
2023-09-25 English
Presentation- FDA Letter Requires Patient Instruction Update 10 pages 1.1MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation discussing the FDA's Complete Response Letter for the NDA filing of Sofpironium Bromide, including regulatory guidance, timelines, and commercial impact. It includes presenter bios, regulatory context, and forward-looking statements. The content is structured as a presentation with slides and images (omitted here), focusing on regulatory updates and company strategy rather than financial statements or formal filings. There is no indication that this is an official report like an Annual Report (10-K), Interim Report (IR), or Audit Report (AR). It is not a transcript of a call, nor a voting result or capital update. The document is a detailed investor or stakeholder presentation about regulatory progress and company plans. Therefore, the best fitting category is Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2023-09-25 English
Trading Halt 2 pages 560.9KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Botanix Pharmaceuticals Ltd regarding a trading halt requested under ASX Listing Rule 17.1. It states that the trading halt is pending the release of an announcement related to FDA communication about a New Drug Application. The document does not contain any financial data, report content, or detailed disclosures but is a short notice about the trading halt itself. Given the short length (2242 characters) and the nature of the content as a regulatory announcement about trading status, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-09-24 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.